Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1267 • ACR Convergence 2021
Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis
Sarah Lieber¹, Iris Navarro-Milln², Musarrat Nahid², Mangala Rajan², Sebastian Sattui¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Emergency department (ED) utilization is associated with worse quality of care and health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE). While frailty…
Abstract Number: 1283 • ACR Convergence 2021
Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies
Karen Costenbader¹, Yoshiyuki Abe², Laurent Arnaud³, George Bertsias⁴, Norma Lynn Fox⁵, Mathew Gibb⁶, Anne Hammer⁵, Alexa Meara⁷, Holly Quasny⁸, David Roth⁵ and Tania Gonzalez-Rivera⁵, ¹Brigham and Women's Hospital, Belmont, MA, ²Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ⁴Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Greece, ⁵GlaxoSmithKline, Collegeville, PA, ⁶Veramed Ltd., Twickenham, United Kingdom, ⁷Ohio State University Wexner Medical Center, Columbus, OH, ⁸GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Glucocorticoids (GC) play an important role in rapid systemic lupus erythematosus (SLE) symptom relief. However, chronic GC use increases organ damage risk; and treatment…
Abstract Number: 1300 • ACR Convergence 2021
Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Hamilton, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada
Background/Purpose: We have previously shown that prolonged clinical remission for ≥10 years is associated with significantly less damage accrual in inception patients with systemic lupus…
Abstract Number: 1461 • ACR Convergence 2021
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
Richard Furie¹, Frédéric Houssiau², Liz Lightstone³, Xueqing Yu⁴, Julia Weinmann-Menke⁵, Yoshiya Tanaka⁶, Angela Jones-Leone⁷, Tania Gonzalez-Rivera⁷, Jennifer Gilbride⁸, Anuradha Madan⁷, Yulia Green⁸ and David Roth⁷, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium, ³Department of Immunology and Inflammation, Imperial College, London, United Kingdom, ⁴Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), ⁵University Hospital Mainz, Mainz, Germany, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷GlaxoSmithKline, Collegeville, PA, ⁸GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose: In the BLISS-LN trial (GSK Study BEL114054; NCT01639339), the administration of belimumab (BEL), a B-lymphocyte stimulator antagonist, resulted in improved renal outcomes in patients…
Abstract Number: 1494 • ACR Convergence 2021
Functional Effects of a Lupus-associated PRKG1 Variant on the RhoA-ROCK Pathway and Response to Type I Interferon
Ruth Fernandez Ruiz¹, Justine Shum², Kayla Van Buren³ and Timothy Niewold⁴, ¹NYU Grossman School of Medicine, New York, NY, ²Marinhealth Medical Center, San Francisco, CA, ³Mnemo Therapeutics, New York, NY, ⁴Colton Center for Autoimmunity NYU School of Medicine, New York, NY
Background/Purpose: Interferon (IFN)-α contributes to susceptibility and severe manifestations in systemic lupus erythematosus (SLE). The PRKG1 rs7897633 variant has been previously identified as the top…
Abstract Number: 1595 • ACR Convergence 2021
Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Courtney Hoge¹, Cristina Drenkard¹, Charmayne Dunlop-Thomas¹, Brad Pearce¹, S Sam Lim² and C. Barrett Bowling³, ¹Emory University, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Duke University, Durham, NC
Background/Purpose: Opportunities for community mobility, which reflects both physical mobility and social participation, during the COVID-19 pandemic have been limited and may have been related…
Abstract Number: 1732 • ACR Convergence 2021
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruoning Ni¹, Jiayi Zheng² and Ruru Guo³, ¹Saint Agnes Healthcare, Baltimore, MD, ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai, China (People's Republic)
Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…
Abstract Number: 1752 • ACR Convergence 2021
Efficacy of Voclosporin in Recent Onset Lupus Nephritis
Meggan Mackay¹, Matt Truman², Nicole England², Vanessa Birardi³ and Paola Mina-Osorio⁴, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc, Rockville, MD, ⁴Aurinia Pharmaceuticals Inc., New York, NY
Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adults with active lupus nephritis (LN) in combination with background immunosuppressive therapy.…
Abstract Number: 1770 • ACR Convergence 2021
Interim Analysis of Cohort 1 in the Mesenchymal Stromal Cell Trial in Systemic Lupus Erythematosis: Safety and Data Management During the Pandemic
Gary Gilkeson¹, Diane Kamen¹, S Sam Lim², Rosalind Ramsey-Goldman³, Kenneth Kalunian⁴, Saira Sheikh⁵, Mariko Ishimori⁶ and Daniel Wallace⁷, ¹Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Northwestern University, Chicago, IL, ⁴UC San Diego, La Jolla, CA, ⁵University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Attune Health, Beverly Hills, CA
Background/Purpose: There is heightened interest in the use of mesenchymal stromal cells (MSCs) for the treatment of autoimmune diseases. There are a number of reports…
Abstract Number: 0131 • ACR Convergence 2021
Association of Numeracy with Medication Non-Adherence in Systemic Lupus Erythematosus
Mithu Maheswaranathan¹, Amanda Eudy², Ann Barr², Catherine Howe³, Stacy Bailey⁴, Susan Hastings¹, Jennifer Rogers², Jayanth Doss², Lisa Criscione-Schreiber¹, Rebecca Sadun², Megan Clowse⁵ and Kai Sun¹, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University Hospital, Durham, NC, ⁴Northwestern University, Evanston, IL, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Over 33% of U.S. adults have limited health literacy or numeracy. Limited health literacy and numeracy have been associated with higher disease activity and…
Abstract Number: 0330 • ACR Convergence 2021
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
Thaisa Cotton¹, Marvin Fritzler², May Choi³, Boyang Zheng⁴, Omid Zahedi Niaki⁵, Louis-Pierre Grenier⁵, Evelyne Vinet⁶, Christian Pineau¹, Luck Lukusa⁷, Fares Kalache⁵ and Sasha Bernatsky¹, ¹McGill University, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University Health Centre, Mont Royal, QC, Canada, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: To determine if a serologic phenotype can be identified in SLE patients with myositis and/or ILD.Methods: Adult SLE patients (without myositis or ILD at…
Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Emily Littlejohn¹, Lingxuan Kong², Kelly Speth², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
Abstract Number: 0523 • ACR Convergence 2021
Transcriptional Subsetting of SLE Patient Cohorts Based on Metabolic Pathway Activity
Diogo Camacho, Jennifer Swantek, Keng Soh, Jurre Kamphorst, Vivek Kaimal, John Monroe and Edward Driggers, Rheos Medicines, Inc, Cambridge, MA
Background/Purpose: Systemic lupus erythematosus is a highly complex, heterogeneous, autoimmune disorder, with diverse clinical presentation and innate and adaptive immune system involvement. There is a…
Abstract Number: 0613 • ACR Convergence 2021
Racial/Ethnic Disparities in Prescription Medications in a Large Urban Medical Center
J. Thomas Berry, William Galanter, Alia Welsh, Sandra Folarin, Reginald Woods and Huan Chang, UIC Medical Center, Chicago, IL
Background/Purpose: African Americans and Hispanics with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) continue to have worse disease-related health outcomes relative to Whites. This…
Abstract Number: 0784 • ACR Convergence 2021
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America
Laura Cannon¹, Scott Wenderfer², Laura Lewandowski³, Jennifer Cooper⁴, Beatrice Goilav⁵, Andrea Knight⁶, Aimee Hersh⁷, Stacy Ardoin⁸ and Rebecca Sadun¹, ¹Duke University, Durham, NC, ²Baylor College of Medicine, Houston, TX, ³NIAMS, NIH, Rockville, MD, ⁴University of Colorado/Children's Hospital Colorado, Denver, CO, ⁵Children's Hospital at Montefiore, Bronx, NY, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷University of Utah, Salt Lake City, UT, ⁸Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) has higher rates of lupus nephritis (LN) than adult-onset SLE, often requiring intensive immunosuppression. This study examined North American…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].